Scientists test Two-Pronged attack on Tough-to-Treat sarcoma
NCT ID NCT05488366
Summary
This small, early-stage study is testing whether it is safe and practical to combine a type of immunotherapy drug (pembrolizumab) with very precise, high-dose radiation (SBRT) for patients with advanced soft-tissue sarcoma. The goal is to see if this combination can help control the cancer in patients whose disease has spread or returned and is not curable with surgery. Researchers will track side effects, how well patients complete treatment, and whether the cancer shrinks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.